Skip to main content
GRAFT POLYMER (UK) PLC logo

GRAFT POLYMER (UK) PLC — Investor Relations & Filings

Ticker · GPL ISIN · GB00BMD1Z199 LEI · 2138005PH7OJRCRPUD88 IL Manufacturing
Open in API
Filings indexed 170 across all filing types
Latest filing 2026-05-19 Annual Report (ESEF)
Country GB United Kingdom
Listing IL GPL

About GRAFT POLYMER (UK) PLC

https://graftpolymer.com/

GRAFT POLYMER (UK) PLC is a technology company specializing in polymer modification and the development of drug delivery systems. The company's core expertise lies in creating proprietary polymer modifiers that enable the combination of otherwise incompatible materials. This process results in cost-effective polymer alloys with enhanced mechanical characteristics, chemical resistance, and fire-retardant properties. Leveraging extensive research and development, the company provides bespoke, 'turn-key' solutions and customized products. Through its GraftBio division, the company also develops bio/pharma applications, including biological supplements and advanced drug delivery systems, supported by a strong intellectual property portfolio.

Recent filings

Filing Released Lang Actions
Annual Report for the year ended 31 December 2025
Annual Report (ESEF) Classification · 100% confidence FY 2025
2026-05-19 English
Annual Report for the year ended 31 December 2025
Annual Report Classification · 96% confidence The document is the complete Annual Report & Financial Statements for the year ended 31 December 2025 for Solvonis Therapeutics PLC, including the full set of financial statements (profit & loss, financial position, cash flows, notes), directors’ report, strategic report, governance report, and independent auditor’s report. It is not merely an announcement or certification but the full annual report itself. FY 2025
2026-05-19 English
CSO Speaks at National Research Meeting
Regulatory Filings
2026-05-05 English
Final Results
Earnings Release Classification · 80% confidence The document is a public announcement of the company’s audited results for the year ended 31 December 2025, with key highlights, CEO/Chairman commentary, and summary financials, and refers readers to the full Annual Report on the website. This matches an initial earnings release for the full-year results rather than the full Annual Report itself. Therefore, it should be classified as an Earnings Release (ER). FY 2025
2026-04-29 English
Appointment of Water Tower Research
Regulatory Filings Classification · 80% confidence The document is a press release via the London Stock Exchange’s RNS service announcing the appointment of an investor‐relations/research firm. It does not present financial results (not an ER or IR), does not issue new shares or raise capital (not CAP or SHA), does not deal with governance, voting results, legal proceedings, M&A, dividends, or director dealings. It is a general corporate/market announcement distributed through RNS without fitting any more specific category. As such, it falls under the fallback “Regulatory Filings” category.
2026-04-22 English
US CNS Executive Order
Regulatory Filings Classification · 94% confidence The document is a corporate press release distributed via the London Stock Exchange’s RNS system, providing a commentary on President Trump’s Executive Order and the company’s view on regulatory developments. It is not a financial report (10-K, IR, ER), not an AGM or investor presentation, nor does it announce dividends, share transactions, M&A, board changes or regulatory/legal proceedings. It is a general regulatory announcement/fall-back press release. Therefore, it should be classified as an RNS.
2026-04-20 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.